Sustained clinical response as an endpoint in treatment trials of Clostridium difficile-associated diarrhea

Antimicrob Agents Chemother. 2012 Aug;56(8):4043-5. doi: 10.1128/AAC.00605-12. Epub 2012 May 21.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Aminoglycosides / therapeutic use
  • Anti-Bacterial Agents / therapeutic use*
  • Clinical Trials, Phase III as Topic
  • Clostridioides difficile / drug effects*
  • Diarrhea / drug therapy*
  • Diarrhea / microbiology
  • Endpoint Determination
  • Enterocolitis, Pseudomembranous / drug therapy*
  • Enterocolitis, Pseudomembranous / microbiology
  • Fidaxomicin
  • Humans
  • Metronidazole / therapeutic use
  • Polymers / therapeutic use
  • Sulfonic Acids
  • Treatment Outcome
  • Vancomycin / therapeutic use

Substances

  • Aminoglycosides
  • Anti-Bacterial Agents
  • Polymers
  • Sulfonic Acids
  • Metronidazole
  • Vancomycin
  • Fidaxomicin
  • styrenesulfonic acid polymer